Lipid profile indices in young people with GCK-MODY and HNF1A-MODY

نویسندگان

چکیده

Despite the fact that most young patients with hyperglycemia are diagnosed type 1 (T1DM) and 2 (T2DM) diabetes, up to 10 % of all cases disease MODY diabetes. The common types GCK-MODY HNF1A-MODY, therefore investigation their clinical laboratory characteristics, including lipid spectrum indicators is high significance. aim this research work was study values in HNF1A-MODY at age from 18 45 years. Lipid profile parameters were investigated 56 aged years by molecular genetic tests, matched sex, body mass index (BMI). No statistically significant differences found for any indicators, however, decrease HDL-C determined significantly more often than GCKMODY. Thus, group persons differs level indices depending on MODY.

برای دانلود باید عضویت طلایی داشته باشید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Treatment of young patients with HNF1A mutations (HNF1A-MODY).

AIM Children and adolescents with a molecular diagnosis of HNF1A-MODY should be treated with oral sulfonylurea according to current International Society for Pediatric and Adolescent Diabetes (ISPAD) guidelines. METHODS We surveyed the German-Austrian DPV database of 50 043 people and included 114 patients with a confirmed molecular-genetic diagnosis of HNF1A mutation and diabetes onset at be...

متن کامل

Meglitinide Analogues in Adolescent Patients With HNF1A-MODY (MODY

For pediatric patients with hepatocyte nuclear factor-1A (HNF1A)– maturity-onset diabetes of the young (MODY 3), treatment with sulfonylureas is recommended. In adults with HNF1A-MODY, meglitinide analogues achieve lower postprandial glucose levels and pose a lower risk of delayed hypoglycemia compared with sulfonylureas. This therapy has not yet been reviewed in pediatric patients. We report o...

متن کامل

Meglitinide analogues in adolescent patients with HNF1A-MODY (MODY 3).

For pediatric patients with hepatocyte nuclear factor-1A (HNF1A)-maturity-onset diabetes of the young (MODY 3), treatment with sulfonylureas is recommended. In adults with HNF1A-MODY, meglitinide analogues achieve lower postprandial glucose levels and pose a lower risk of delayed hypoglycemia compared with sulfonylureas. This therapy has not yet been reviewed in pediatric patients. We report on...

متن کامل

Circulating ghrelin level is higher in HNF1A–MODY and GCK–MODY than in polygenic forms of diabetes mellitus

Ghrelin is a hormone that regulates appetite. It is likely to be involved in the pathophysiology of varying forms of diabetes. In animal studies, the ghrelin expression was regulated by the hepatocyte nuclear factor 1 alpha (HNF1A). Mutations of the HNF1A gene cause maturity onset diabetes of the young (MODY). We aimed to assess the circulating ghrelin levels in HNF1A-MODY and in other types of...

متن کامل

GCK-MODY (MODY 2) Caused by a Novel p.Phe330Ser Mutation

Maturity onset diabetes of the young (MODY) is a monogenic form of diabetes inherited as an autosomal dominant trait. The second most common cause is GCK-MODY due to heterozygous mutations in the GCK gene which impair the glucokinase function through different mechanisms such as enzymatic activity, protein stability, and increased interaction with its receptor. The enzyme normally acts as a glu...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

ژورنال

عنوان ژورنال: ????????????

سال: 2022

ISSN: ['2222-5250']

DOI: https://doi.org/10.52727/2078-256x-2021-17-4-43-47